Drug Profile

XL 265

Alternative Names: XL-265

Latest Information Update: 28 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Exelixis; Unknown
Class Antineoplastics; Small molecules
Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto-oncogene protein c-mer inhibitors; TYRO3 receptor protein tyrosine kinase antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Feb 2024 No recent reports of development identified for preclinical development in Cancer in USA
13 Jan 2020 Preclinical trials in Cancer in USA (unspecified route) before January 2020
12 Jan 2020 Exelexis announces intention to file an IND application with the US FDA in USA for Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com